Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Pozycja w akcjach #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Cena akcji
$0.25974701
Ostatnia synchronizacja: 2025-01-06
Kapitalizacja rynkowa
$2.04M
Zmiana (1 dzień)
0.74%
Zmiana (1 rok)
0.00%
Kraj
FR
Handel Acticor Biotech SAS (ALACT)

Kategoria

Wskaźnik P/B dla Acticor Biotech SAS (ALACT)
Wskaźnik P/B na dzień September 2026 TTM: -0.57
Według najnowszych raportów finansowych i ceny akcji Acticor Biotech SAS, obecny wskaźnik P/B (TTM) wynosi -0.57. Na koniec 2022 wynosił -33.19.
Historia wskaźnika P/B dla Acticor Biotech SAS od 2010 do 2026
Wskaźnik P/B na koniec każdego roku
Rok Wskaźnik P/B Zmień
2026 (TTM) -0.57 -91.38%
2023 -6.59 -80.15%
2022 -33.19 -1,126.36%
2021 3.23 -87.62%
2020 26.12 538.96%
2019 4.09 17.85%
2018 3.47 -160.01%
2017 -5.78 -511.84%
2016 1.40 2.83%
2015 1.37 7.92%
2014 1.26 5.23%
2013 1.20 -8.34%
2012 1.31 -12.44%
2011 1.50 -91.22%
2010 17.05 0.00%
Wskaźnik P/B dla podobnych firm lub konkurentów
Firma Wskaźnik P/B Różnica wskaźnika P/B Kraj
6.5144 -1,247.10%
US
7.3983 -1,402.75%
NL
3.9974 -803.89%
AU
8.5918 -1,612.91%
US
- -
CH